What should be evaluated before starting neoadjuvant chemotherapy in a patient with pancreatic head adenocarcinoma?

Pre-NACT Evaluation for Pancreatic Head Adenocarcinoma

Before initiating neoadjuvant chemotherapy for pancreatic head cancer, you must establish borderline resectable or locally advanced disease status, confirm adequate performance status (ECOG 0-1), ensure bilirubin ≤1.5× ULN, and exclude metastatic disease through comprehensive staging.

Critical Resectability Assessment

The primary determinant of NACT candidacy is tumor resectability status. NACT is specifically indicated for borderline resectable or locally advanced disease with vessel encasement, NOT for upfront resectable disease 1. For truly resectable pancreatic head cancer, neoadjuvant therapy should only be performed within clinical trials 1.

Imaging Requirements for Staging

You need high-quality cross-sectional imaging to assess vascular involvement:

• Multiphase CT abdomen/pelvis with pancreatic protocol or MRI with MRCP to evaluate tumor-vessel relationships and assess for intra-abdominal metastases 2
• CT chest to exclude pulmonary metastases 1
• Consider staging laparoscopy for left-sided large tumors, elevated CA19-9, or when neoadjuvant treatment is planned—this detects occult peritoneal/liver metastases in <15% of patients that would change management 1

Apply NCCN criteria for resectability/irresectability to categorize the tumor 1.

Performance Status and Physiologic Fitness

Performance status is non-negotiable for intensive regimens:

• ECOG 0-1 required for FOLFIRINOX, the preferred neoadjuvant regimen 1, 3
• Age ≤75 years preferred for FOLFIRINOX, though not absolute 1, 3
• Evaluate comorbidities that would preclude surgery, especially in patients >75-80 years 1

Laboratory Parameters

Baseline bilirubin ≤1.5× ULN is mandatory for FOLFIRINOX eligibility 1. If biliary obstruction is present:

• Perform endoscopic stenting to relieve obstruction BEFORE starting chemotherapy 1
• Metal stents preferred for life expectancy >3 months 1
• Recheck bilirubin after decompression before initiating therapy

Obtain baseline CA19-9 (if patient is not Lewis antigen-negative) for treatment monitoring and prognostic assessment, but only in absence of cholestasis 1, 2. Elevated CA19-9 may prompt consideration of staging laparoscopy 1.

Check baseline neutrophil-to-lymphocyte ratio (NLR)—emerging evidence suggests NLR >3.3 identifies patients who may particularly benefit from intensified neoadjuvant therapy with FOLFIRINOX ± radiation 4.

Tissue Diagnosis Considerations

Biopsy is NOT mandatory before neoadjuvant therapy if imaging is characteristic and surgery with curative intent is planned 1. However, obtain cytologic/histologic confirmation when:

• Imaging findings are ambiguous
• Patient will receive neoadjuvant therapy
• Use EUS-guided biopsy (preferred method) 1
• Avoid percutaneous sampling due to risk of peritoneal seeding 1

Goals of Care Discussion

Document advance directives, treatment goals, patient preferences, and support systems before initiating therapy 2. This is particularly important given that patients who develop metastases during neoadjuvant chemotherapy or progress locally are NOT candidates for subsequent surgery 1.

Multidisciplinary Evaluation

Mandatory multidisciplinary team review including medical oncology, surgical oncology, radiation oncology, and radiology to formulate treatment plan 2. This ensures consensus on resectability status and optimal treatment sequencing.

Key Pitfalls to Avoid

• Do not give NACT to truly resectable disease outside clinical trials—these patients should proceed directly to surgery followed by adjuvant therapy 1
• Do not start FOLFIRINOX with elevated bilirubin—decompress first 1
• Do not proceed with NACT if performance status is poor (ECOG ≥2)—these patients cannot tolerate intensive regimens 3
• Do not skip staging laparoscopy in high-risk patients (large tumors, high CA19-9)—it prevents futile laparotomy in 15% 1

The evidence base for these recommendations comes primarily from ESMO-ESDO guidelines [1-1] and NCCN guidelines 3, with FOLFIRINOX established as the preferred regimen based on the PRODIGE trial showing dramatic survival improvements (11.1 vs 6.8 months OS) in metastatic disease 3, extrapolated to the neoadjuvant setting for borderline resectable/locally advanced disease.